Oral retinoic acid as therapy for congenital ichthyosiform erythroderma

Eriksen, L.; Cormane, R. H.

doi:10.1111/j.1365-2133.1975.tb03086.x

Cited by 17 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral retinoic acid has been beneficial in patients with both classical and bullous congenital ichthyosiform erythrodermia (Eriksen & Cormane, 1975). Favourable results have also been obtained in patients with lamellar ichthyosis, ichthyosis vulgaris, Darier's disease, pityriasis rubra pilaris, keratosis palmaris et plantaris and cystic acne.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic evaluation of the oral retinoid Ro 10-9359 in several non-psoriatic dermatoses

Viglioglia

1980

Br J Dermatol

View full text Add to dashboard Cite

Forty-five patients suffering from various genodermatoses and erythematous, scaling, non-psoriatic dermatoses were treated orally with the aromatic derivative of retinoic acid, Ro 10-9359 (Tigason). In the genodermatoses the best results were obtained in ichthyosis, keratodermias and Darier's disease (95.6% good to excellent). Among the erythematous scaling diseases, treatment was effective in lichen planus, parapsoriasis and pityriasis rubra pilaris (53.3% good to excellent results). In comparison with therapies previously employed Ro 10-9359 was more effective. No serious side-effects were noted.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic evaluation of the oral retinoid Ro 10-9359 in several non-psoriatic dermatoses

Viglioglia

1980

Br J Dermatol

View full text Add to dashboard Cite

show abstract

“…Peck and Yoder [3] used doses of 0.5-7.4 mg/kg/day for up to 55 weeks with minimal undesirable effects; the average dose they recom mended was 2 mg/kg/day. We gave the retinoid in a single daily dose, ac cording to the report of Eriksen and Cormane [6]. They observed a better therapeutic effect with this schedule.…”

Section: Commentsmentioning

confidence: 99%

Oral Retinoid (Ro 10-9359) in Children with Lamellar Ichthyosis, Epidermolytic Hyperkeratosis and Symmetrical Progressive Erythrokeratoderma

Tamayo¹,

Ruíz-Maldonado²

1980

Dermatology

View full text Add to dashboard Cite

8 children with lamellar ichthyosis, 1 with epidermolytic hyperkeratosis and 5 with symmetrical progressive erythrokeratoderma were treated with a new aromatic retinoid (Ro 10-9359). Clinical improvement was dramatic. The children acquired an appearance never obtained before with other managements. The treatment had to be maintained to prevent recurrence. The tolerance to the drug was good. The side-effects were minimal and tended to disappear after several months of treatment. Our results suggest that because of its efficacy, good tolerance and easy administration, the oral retinoid Ro 10-9359 is at present the treatment of choice for the great ichthyotic disorders of children.

show abstract

“…Etretinate has been used in a large number of keratinization disorders (5), including a severe form of lamellar ichthyosis (3)(4)(5)(6)(7). All these reports dealt with children over 4 years of age or young adults.…”

Section: Discussionmentioning

confidence: 99%

Failure of Etretinate Therapy in Twins with Severe Congenital Lamellar Ichthyosis

Waisman¹,

Rachmel²,

Metzker³

et al. 1989

Pediatric Dermatology

View full text Add to dashboard Cite

We cared for twin females with severe lamellar exfoliation of the newborn (collodion babies) and a family history of death of two brothers at age 3 months. The twins were given a controlled trial of etretinate (Ro 10-9359, Tigason) after not responding to other therapeutic modalities. One of the infants received 1 mg/kg body weight of the drug for 24 hours, while her identical twin sister did not have the medication. Monthly skin biopsies taken from both patients during nine months of therapy did not demonstrate any histologic difference under light microscopy. The clinical course in both infants was basically the same. Etretinate plasma level measurements proved that the drug was absorbed from the gastrointestinal tract. We conclude that in the very severe forms of congenital lamellar ichthyosis, oral retinoids may fail to produce any beneficial effects.

show abstract

Oral retinoic acid as therapy for congenital ichthyosiform erythroderma

Cited by 17 publications

References 7 publications

Therapeutic evaluation of the oral retinoid Ro 10-9359 in several non-psoriatic dermatoses

Therapeutic evaluation of the oral retinoid Ro 10-9359 in several non-psoriatic dermatoses

Oral Retinoid (Ro 10-9359) in Children with Lamellar Ichthyosis, Epidermolytic Hyperkeratosis and Symmetrical Progressive Erythrokeratoderma

Failure of Etretinate Therapy in Twins with Severe Congenital Lamellar Ichthyosis

Contact Info

Product

Resources

About